Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
indocyanine green + neomannosyl human serum albumin
- Development stage
- Unknown
- Lead developer
- Hamamatsu Photonics
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
A macrophage-targeted fluorescent imaging agent composed of **indocyanine green** (ICG), a near-infrared fluorophore, conjugated to **neomannosyl human serum albumin** (MSA), a recombinant human serum albumin modified with neomannose. This combination is developed principally for **sentinel lymph node (SLN) mapping** during oncologic surgery by targeting macrophage mannose receptors, facilitating precise intraoperative visualization with near-infrared fluorescence. The mechanism leverages ICG’s fluorescence, while the neomannosyl modification increases uptake in SLNs by targeting macrophage-rich regions, thus enhancing the signal-to-background ratio[5]. The agent has been studied for potential use in esophageal cancer and aims to overcome limitations of free ICG, such as rapid diffusion and lower selectivity.
- Other names
- indocyanine green-neomannosyl human serum albuminICG-neomannosyl human serum albuminICG:MSA
02
Targets
MRC1 (Mannose Receptor C-type 1)
Beyond the preview
Go deeper on indocyanine green + neomannosyl human serum albumin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on indocyanine green + neomannosyl human serum albumin.